Altered molecular pathways in gliomas: an overview of clinically relevant issues.
about
Loss of protein inhibitors of activated STAT-3 expression in glioblastoma multiforme tumors: implications for STAT-3 activation and gene expressionPrevalence of copy-number neutral LOH in glioblastomas revealed by genomewide analysis of laser-microdissected tissues.Current trends in intraoperative optical imaging for functional brain mapping and delineation of lesions of language cortex.Protein expression of platelet-derived growth factor receptor correlates with malignant histology and PTEN with survival in childhood gliomas.The expression of cytoglobin as a prognostic factor in gliomas: a retrospective analysis of 88 patientsMolecular pathology in adult gliomas: diagnostic, prognostic, and predictive markersNovel therapeutics in adult malignant brain gliomas.Genetic strategies for brain tumor therapy.Chemotherapy for malignant glioma.State of the art chemotherapeutic management of pediatric brain tumors.Malignant gliomas: strategies to increase the effectiveness of targeted molecular treatment.Molecular pathways triggering glioma cell invasion.Blood-brain barrier and chemotherapeutic treatment of brain tumors.Recurrent glioblastoma multiforme: advances in treatment and promising drug candidates.Glioblastoma multiforme: evidence-based approach to therapy.Signal transducer and activator of transcription-3: a molecular hub for signaling pathways in gliomasConstitutive EGFR signaling in oligodendrocyte progenitors leads to diffuse hyperplasia in postnatal white matterIn vivo detection of c-Met expression in a rat C6 glioma modelDifferential proteomics analysis of low- and high-grade of astrocytoma using iTRAQ quantificationGlioma stem cell signaling: therapeutic opportunities and challenges.The molecular profile of microglia under the influence of glioma.Towards developing biomarkers for glioblastoma multiforme: a proteomics view.Anti-EGFR therapy combined with neuromedin B receptor blockade induces the death of DAOY medulloblastoma cells.A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma.Taurine: a potential marker of apoptosis in gliomas.Nanomedicine associated with photodynamic therapy for glioblastoma treatment.New molecular targets and novel anticancer treatments: emerging trends in neuro-oncology.
P2860
Q24619748-FCCA33D6-D012-4B7F-9AA1-EDC9592399F5Q33359490-DD641921-9F22-43D9-850B-D6852B26ACBBQ33368936-9523F975-FE92-4D84-80DD-F42C600CC57EQ34191508-66E1D5DE-0EF7-402F-BC74-D1B597F99113Q34729001-3E6E9D7F-C745-4137-95EA-BF01336E8BE6Q34815207-7FC1B6F6-9933-4DD4-BB11-212C09963ECEQ36187046-529F6602-ABED-4636-A3FD-F7407DA7BBD9Q36247099-B72AB254-EF57-4732-8F4D-9BB9A893BC99Q36307802-399FA9C8-48D4-4CF7-ABC7-88220C165493Q36492376-B2BCFBCD-B5EC-4377-9CAE-CFFD5856E00FQ36499234-C710084A-BDAC-4059-9E06-F0DA7DECFDE2Q36528894-95714AAE-5F24-4BAB-93BD-E7A282942A86Q36558683-F7B38E84-8D3C-48F6-8013-F6BEA185C30BQ36668246-3B332803-23F9-4BDF-8A09-4753930E261DQ37030797-F31A2E88-8C30-46E1-9C62-3C520DE67A56Q37174303-93C63533-DF6A-40C2-AB23-7C74A6C67127Q37264074-43145F46-A816-4198-B140-2500E75849DFQ37296362-7181A6A8-D686-49AF-91B9-F368CCEB938EQ37301385-CE3236C1-9C41-49EA-B710-7D50A540286DQ37752381-39C26F3C-BBB1-40CD-9FBE-48CCE47D2468Q38008966-3B778739-9B27-4B6C-B6FF-A2E45ADD74FBQ38239173-0ACAEC6D-6770-433B-830C-D127D1D4D6EAQ39087605-88A7951A-4495-46F0-9A6A-C71E86978C1DQ40280414-F776112A-30AE-4830-B33F-AABB9E405996Q43165528-53B83AC3-721C-4C9C-BA4A-476F96D1B1C9Q47097576-11419AD7-D17D-4ED2-B350-3763BDC2F26CQ48440244-5DE1750F-6021-4F84-8514-57D6F4CFEEF7
P2860
Altered molecular pathways in gliomas: an overview of clinically relevant issues.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Altered molecular pathways in gliomas: an overview of clinically relevant issues.
@ast
Altered molecular pathways in gliomas: an overview of clinically relevant issues.
@en
type
label
Altered molecular pathways in gliomas: an overview of clinically relevant issues.
@ast
Altered molecular pathways in gliomas: an overview of clinically relevant issues.
@en
prefLabel
Altered molecular pathways in gliomas: an overview of clinically relevant issues.
@ast
Altered molecular pathways in gliomas: an overview of clinically relevant issues.
@en
P1433
P1476
Altered molecular pathways in gliomas: an overview of clinically relevant issues.
@en
P2093
C David James
Ravi D Rao
P304
P356
10.1053/J.SEMINONCOL.2004.07.002
P577
2004-10-01T00:00:00Z